Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00414076 · OUTCOME

Progression Free Survival (PFS)

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma · Source last updated 2018-11-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Every 12 weeks

What was measured

Number of participants progressed or death from study entry.

Analysis population: 1 out of 4 participants in the Letrozole arm progressed on study. 2 participants progressed in standard of care

Groups in this outcome

Letrozole

Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks. Letrozole: 2.5 mg Tablet By Mouth Daily for 12 Weeks.

Standard of Care

Patients receive no treatment. Follow up every 3 months.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Letrozole4
Standard of Care5

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Letrozole1Not reportedNot reportedNot reportedNot reported
Standard of Care2Not reportedNot reportedNot reportedNot reported
Complete source fields
calculate Pct
false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      5
    units
    Participants
description
Number of participants progressed or death from study entry.
groups
  1. description
    Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks. Letrozole: 2.5 mg Tablet By Mouth Daily for 12 Weeks.
    id
    OG000
    title
    Letrozole
  2. description
    Patients receive no treatment. Follow up every 3 months.
    id
    OG001
    title
    Standard of Care
param Type
COUNT_OF_PARTICIPANTS
population Description
1 out of 4 participants in the Letrozole arm progressed on study. 2 participants progressed in standard of care
reporting Status
POSTED
time Frame
Every 12 weeks
title
Progression Free Survival (PFS)
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice